A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis

NCT07008378 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

BIOLOGICAL: P-CD19CD20-ALLO1 Cells
DRUG: Cyclophosphamide
DRUG: Fludarabine

Sponsor

Genentech, Inc.

Collaborators

[object Object]